{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:10:31Z","timestamp":1780758631739,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jiph.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:41:02Z","timestamp":1658493662000},"page":"961-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia"],"prefix":"10.1016","volume":"15","author":[{"given":"Cheng-Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Kuo","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Tung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Kuei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chi","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"10303","key":"10.1016\/j.jiph.2022.07.008_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jiph.2022.07.008_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jiph.2022.07.008_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jiph.2022.07.008_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.rmed.2013.04.003","article-title":"CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study","volume":"107","author":"Arnold","year":"2013","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.jiph.2022.07.008_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3947\/ic.2018.50.4.287","article-title":"Disease burden and etiologic distribution of community-acquired pneumonia in adults: evolving epidemiology in the era of pneumococcal conjugate vaccines","volume":"50","author":"Heo","year":"2018","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jiph.2022.07.008_bib7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1183\/09031936.00168811","article-title":"Community-acquired pneumonia in outpatients: aetiology and outcomes","volume":"40","author":"Cill\u00f3niz","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/nu14010198","article-title":"Significance of the modified NUTRIC score for predicting clinical outcomes in patients with severe community-acquired pneumonia","volume":"14","author":"Tseng","year":"2021","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.jiph.2022.07.008_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106184","article-title":"Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections","volume":"56","author":"Bassetti","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/dkw402","article-title":"Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis","volume":"72","author":"Battle","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1183\/09031936.06.00049105","article-title":"Appropriateness and delay to initiate therapy in ventilator-associated pneumonia","volume":"27","author":"Luna","year":"2006","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jiph.2022.07.008_bib12","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jiph.2022.07.008_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jiph.2016.10.005","article-title":"Relative potency of different generic brands of Piperacillin-Tazobactam: implications for public health","volume":"10","author":"Das","year":"2017","journal-title":"J Infect Public Health"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2007.12.010","article-title":"In vitro potency evaluations of various piperacillin\/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation","volume":"61","author":"Jones","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diagmicrobio.2013.01.024","article-title":"More potency assay results for generic non-USA lots of piperacillin\/tazobactam and initial reports for generic meropenem compounds marketed in the USA","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2022.07.008_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diagmicrobio.2009.06.012","article-title":"Expanded studies of piperacillin\/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots","volume":"65","author":"Moet","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2022.07.008_bib17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2147\/IDR.S313828","article-title":"Clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"14","author":"Chen","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106491","article-title":"Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients","volume":"59","author":"Huang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jiph.2022.07.008_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bjid.2019.06.010","article-title":"Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia","volume":"23","author":"Ord\u00f3\u00f1ez","year":"2019","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2022.07.008_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.diagmicrobio.2016.04.015","article-title":"Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin","volume":"85","author":"Sun","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2022.07.008_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/antibiotics9020077","article-title":"In vitro antimicrobial activity of various cefoperazone\/sulbactam products","volume":"9","author":"Sheu","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2022.07.008_bib22","first-page":"10","article-title":"Comparison of pharmaceutical characteristics between brand-name meropenem and its generics","author":"Yang","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2022.07.008_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2014.05.001","article-title":"Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers","volume":"85","author":"Blandizzi","year":"2014","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.jiph.2022.07.008_bib24","first-page":"2311","article-title":"Pharmacokinetics of four different brands of colistimethate and formed colistin in rats","volume":"68","author":"He","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2022.07.008_bib25","first-page":"153","article-title":"Generic inequivalence between two brands of chloramphenicol capsule","volume":"3","author":"Bugaje","year":"1976","journal-title":"West Afr J Pharm Drug Res"},{"issue":"1","key":"10.1016\/j.jiph.2022.07.008_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13756-021-00977-w","article-title":"Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study","volume":"10","author":"Feng","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"10.1016\/j.jiph.2022.07.008_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10156-012-0437-0","article-title":"Generic antibiotics in Japan","volume":"18","author":"Fujimura","year":"2012","journal-title":"J Infect Chemother"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:14:36Z","timestamp":1761750876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1876034122001861"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.07.008","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}